The FINANCIAL -- On July 23, CSRC initiated an investigation into Changsheng Bio-technology Co. Ltd. (hereinafter as “the Company”) for suspected illegal information disclosure.
On the same day, the Company announced that if the regulatory department finally decides the Company as being involved in material illegal behaviors or being transferred to the public security organ because of the aforesaid investigation, the Company shares would be subject to delisting risk warnings, listing suspension or delisting according to the SZSE Rules Governing Share Listing.
In order to ensure that the Company shareholders abide by the CSRC Provisions on the Share Lessening by the Shareholders, Directors, Supervisors and Senior Management of Listed Companies and the SZSE Implementation Rules on the Share Lessening by the Shareholders, Directors, Supervisors and Senior Management of Listed Companies, SZSE has imposed restriction on the shares held by the Company's major shareholders, directors, supervisors and senior management.
Furthermore, according to the notification by the State Drug Administration, the Company has been ordered to cease its production and it disclosed that the production of freeze-dried rabies vaccines for human use and "Diphtheri, Tetanus and Acellular pertussis Combined Vaccine, Adsorbed" has currently discontinued. SZSE will closely follow the progress of relevant matters. If the Company involves in the circumstances where the said operation and production activities have been severely influenced, which is stated in Article 13.3.1 of the Rules Governing Share Listing, SZSE will impose special treatment risk warnings on the Company shares.